Jonathan Fox
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- SARS-CoV-2 and COVID-19 Research 4
- COVID-19 Clinical Research Studies 3
-
- interferon and immune responses 3
Jonathan Fox
11 papers receiving 2.2k citations
Jonathan Fox's Hit Papers
Peers
Comparison fields: 5 of 117
- Infectious Diseases 1.1k
- Applied Microbiology and Biotechnology 48
- Neurology 351
- Internal Medicine 59
- Immunology 290
Countries citing papers authored by Jonathan Fox
This map shows the geographic impact of Jonathan Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Fox more than expected).
Fields of papers citing papers by Jonathan Fox
This network shows the impact of papers produced by Jonathan Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Fox. The network helps show where Jonathan Fox may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 4 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2018 | 138 | |
| 7 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 121 |
| 8 | 2023 | 83 | |
| 9 | 2023 | 56 | |
| 10 | 2020 | 11 | |
| 11 | 2024 | 8 |
About Jonathan Fox
Jonathan Fox is a scholar working on Infectious Diseases, Immunology, Emergency Medical Services, Statistics, Probability and Uncertainty and Genetics, having authored 11 papers that have together received 2.3k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (4 papers), COVID-19 Clinical Research Studies (3 papers), interferon and immune responses (3 papers), Liver Disease Diagnosis and Treatment (1 paper), Delphi Technique in Research (1 paper), Respiratory viral infections research (1 paper), Diabetes and associated disorders (1 paper) and Meta-analysis and systematic reviews (1 paper). The work is most often cited by research in Infectious Diseases (1.1k citations), Applied Microbiology and Biotechnology (48 citations), Neurology (351 citations), Internal Medicine (59 citations) and Immunology (290 citations). Jonathan Fox has collaborated with scholars based in United Kingdom, Australia and Indonesia. Their work appears in journals such as Nature, The Lancet, Kidney International, Human Genetics and Genomics Advances and Nephrology Dialysis Transplantation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.